# **BEST AVAILABLE COPY**

CORRECTED VERSION\*

PCT

# WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



### INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:		(11) International Publication Number: WO 99/46284
C07K 7/06, 7/08, A61K 38/08, 38/10, 31/195, G01N 33/68, 33/566, A61K 47/48	A3	(43) International Publication Date: 16 September 1999 (16.09.99)
(21) International Application Number: PCT/US (22) International Filing Date: 10 March 1999 (		CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
(30) Priority Data:		Published  With international search report.  Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.
(71) Applicant: THE BURNHAM INSTITUTE [US/US North Torrey Pines Road, La Jolla, CA 92037 (U		(88) Date of publication of the international search report: 6 April 2000 (06.04.00)
(72) Inventors: RAIOTTE, Daniel; 517 1/2 Stratford C Mar, CA 92104 (US). PASQUALINI, Renata; 2 Sierra Avenue, #29, Solana Beach, CA 92075 (I OSLAHTI, Erkki, I.; P.O. Box 1054, Rancho San 92067 (US).	707 Sou US). R	h   
(74) Agents: GASHLER, Andrea, L. et al.; Campbell & Fl Suite 700, 4370 La Jolla Village Drive, San D 92122 (US).		

(54) Title: MOLECULES THAT HOME TO VARIOUS SELECTED ORGANS OR TISSUES

#### (57) Abstract

The present invention provides molecules that selectively home to various normal organs or tissues, including to lung, pancreas, skin, retina, prostate, ovary, lymph node, adrenal gland, liver or gut; and provides molecules that selectively home to tumor bearing organs or tissues, including to pancreas bearing a pancreatic tumor or to lung bearing a lung tumor. The invention also provides conjugates, comprising an organ or tissue homing molecule linked to a moiety. Such a molety can be, for example, a therapeutic agent or a detectable agent. The invention also provides a method of identifying a membrane dipeptidase (MDP)-binding homing molecule that selectively homes to lung endothelium. The method includes the steps of contacting MDP with one or more molecules; and determining specific binding of a molecule to the MDP, where the presence of specific binding identifies the molecule as a MDP-binding homing molecule that selectively homes to lung endothelium. Such MDP-binding homing molecules can be linked to a moiety and, when administered to a subject as a conjugate, can selectively direct the molety to lung endothelium in the subject.

#### FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	RS	Spain	LS	Leantho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	sk	Slovakia
AT	Austria	FR	France	LU	Luxer:ibourg	SN	Scncgal
ΛÜ	Australia	GA '	Gabos	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monata	TD	Chad
BA	Bosnia and Herzegovina	GB	Georgia	MD	Republic of Mokiova	TG	Togo
BB	Barbados	GH	Ghana	MG	Medagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yogoslav	TM	Turkmenistan
BF	Burkina Paso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobego
BJ	Benin	Œ	Ireland	MN	Mongolia	UA	Ukrainc
BR	Brazil	п.	îsrael	MR	Mauritania	UC	Uganda
BY	Belarus	IS.	Iceland	MW	Malawi	US	United States of America
CA	Canada	п	linly	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NB	Niger	VN	Viet Nam
·CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Core d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	ΚZ	Kazaksian	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DB	Germany	u	Liechtenstein	SD	Sudan		
DK	Denmark	1.K	Sri Lanko	SE	Sweden		
KR	Estonia	LR	Liberia	SG	Singapore		

Inten nel Application No PCT/US 99/05284

IPC 6	CO7K7/06 CO7K7/08 A61K38/ G01N33/68 G01N33/566 A61K47/		A61K31/195	
According to	tratemational Patent Classification (IPC) or to both national classific	cetion and IPC		
B. FIELDS	SEARCHED			
Minimum do IPC 6	currentation searched (classification system followed by classification CO7K A61K GO1N CO7C	tion symbols)		
	ion searched other than minimum documentation to the extent that			
	ata base consulted during the internetional search (name of data by	ose ara, where prouval, octivi to	ine useuj	
	Citation of document, with indication, where appropriate, of the re	lavest seconds	Relevant to claim No.	
Category *	Cased of cocument, with indication, where appropriate, or the re	Mevalik pesseges	Pictorale to Claim No.	
A	WO 97 10507 A (JOLLA CANCER RES 20 March 1997 (1997-03-20) cited in the application	FOUND)	1-7, 84-88, 91-99, 103-123	
	the whole document			
A	POLGREN A ET AL: "IDENTIFICATIO MUSCLE HOMING SEQUENCES BY USING DISPLAY LIBRARIES OF PEPTIDES" TUMOR BIOLOGY, vol. 18, 1 January 1997 (1997-01 77 XP002910201 the whole document	PHAGE -01), page	1-7, 84-88, 91-99, 103-123	
		-/	·	
X Furti	ner documents are listed in the continuation of box C.	Patent family members	are listed in annox.	
*Special categories of cited documents:  "A" document delining the general state of the left which is not considered to be of particular relevance.  "E" eerifer document but published on or after the international filing date.  "L" document which may throw doubts on priority claim(e) or which is cited to establish the publication date of another citation or other special reason (as specified).  "O" document referring to an oral disclosure, use, exhibition or other means.  "P" document published prior to the international filing date but tater than the priority of able failing date but tater than the priority of able failing date but tater than the priority of able failing date but tater than the priority of able failing date but tater than the priority of able failing date but tater than the priority of able failing date but tater than the priority of able failing date but tater than the priority of able failing date but tater than the priority of able failing date but the consideration of the same patent family.				
	actual completion of the international search  8 January 2000	Date of mailing of the internal 1 5. 0	stional search report 2. 2000	
Name and r	nailing address of the ISA European Patent Office, P.B. 5918 Patentiaan 2 NL - 2250 HV Rijawik Tet (-91-70) 940-2040, Tx. 31 651 epo nl. Fart (-91-77) 940-2016	Authorized officer Hoekstra, S		

Inter. nel Application No PCT/US 99/05284

C (Coction	etion) DOCUMENTS CONSIDERED TO BE RELEVANT	CT/US 99/05284
	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
<b>A</b> .	ARAP E.A.: "Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model" SCIENCE, vol. 279, 16 January 1998 (1998-01-16), pages 377-380, XP002115543 LANCASTER, PA US the whole document	1-7, 84-88, 91-99, 103-123
A	PASQUALINI R ET AL: "ORGAN TARGETING IN VIVO USING PHAGE DISPLAY PEPTIDE LIBRARIES" NATURE, vol. 380, 28 March 1996 (1996-03-28), pages 364-366, XP002055919 ISSN: 0028-0836 abstract	1-7, 84-88, 91-99, 103-123
A	WO 97 26918 A (SPRINGER CAROLINE JOY ;MARAIS RICHARD (GB); CANCER RES CAMPAIGN TE) 31 July 1997 (1997-07-31) the whole document	1-7, 84-88, 91-99, 103-123
P,A	WO 98 10795 A (BURNHAM INST) 19 March 1998 (1998-03-19) the whole document	1-7, 84-88, 91-99, 103-123
T	RAJOTTE, D. ET AL.: "Membrane dipeptidase is th ereceptor for a lung-targeting peptide identified by in vivo phage display."  JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 17, 23 April 1999 (1999-04-23), pages 11593-11598, XP000869582 the whole document	84-88, 91-99, 103-123

Ω

Ini. ational application No. PCT/US 99/05284

Boxi	Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)
This Inte	emational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X	Claims Nos.: 1,3-7(all partially) because they rotate to subject matter not required to be searched by this Authority, namely:  see FURTHER INFORMATION sheet PCT/ISA/210
2. X	Claims Nos.:  1,3-7(all partially) because they relate to parts of the international Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  see FURTHER INFORMATION sheet PCT/ISA/218
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)
This Inte	ernational Searching Authority found multiple inventions in this international application, as follows:
	see additional sheet
1.	As all required additional search fees were timely paid by the applicant, this international Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. X	As only some of the required additional search less were timely peid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Noc.:  1-7, 84-88, 91-99, 103-123
4 🗆	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remari	The additional search (see were accompanied by the applicant's protest.  X No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1998)

### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

#### Continuation of Box I.1

Although claim 5 encompasses diagnostic methods practised on the human/animal body and claim 7 and , 88, 91-99 and 103-123 are directed to methods of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Claims Nos.: 1,3-7(all partially)

Rule 39.1(iv) PCT - Diagnostic method practised on the human or animal body Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

Continuation of Box I.2

Claims Nos.: 1,3-7(all partially)

Present claim 1 relates to a compound defined by reference to a desirable characteristic or property, namely the selective homing to the

vasculature of the prostate.

The claim covers all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claim so lacks support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning.

The claim also lacks clarity (Article 6 PCT). An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims 1-7 which appear to be clear, supported and disclosed, namely those parts relating to the compounds defined in claim 2 and in TABLE 7.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

#### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-7

Peptides that selectivly home to the vasculature of the prostate and their use for diagnostic and medical purposes.

2. Claims: 8-16,89,90,100-102(all complete), 88,97-99,109-114, 117(all partially)

3. Claims: 17-24

Peptides that selectivly home to the vasculature of the skin and their use for diagnostic and medical purposes.

4. Claims: 25-33

Peptides that selectivly home to the vasculature of the retina and their use for diagnostic and medical purposes.

5. Claims: 34-41

Peptides that selectivly home to the vasculature of the pancreas and their use for diagnostic and medical purposes.

6. Claims: 42-52

Peptides that selectivly home to the vasculature of the gut and their use for diagnostic and medical purposes.

7. Claims: 53-59

Peptides that selectivly home to the vasculature of the ovary and their use for diagnostic and medical purposes.

8. Claims: 60-70

Peptides that selectivly home to the vasculature of the adrenal gland and their use for diagnostic and medical purposes.

9. Claims: 71-77

### FURTHER INFORMATION CONTINUED FROM PCT/ISAV 210

Peptides that selectivly home to the vasculature of the liver and their use for diagnostic and medical purposes.

10. Claims: 78-83

Peptides that selectivly home to the lymph node and their use for diagnostic and medical purposes.  $\label{eq:perturb} % \begin{array}{ll} & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ \end{array}$ 

11. Claims: 84-87,91-96,103-108,115,116,118-123(all complete), 88,97-99,109-114,117

Method of identifying a MDP-binding homing molecule that selectively homes to lung endothelium, the compounds obtained and their diagnostic and medical use

page 2 of 2

information on patent family members

PCT/US 99/05284

Patent document cited in search report		Publication date	Patent family member(s)		Publication date	
WO 9710507	Α	20-03-1997	US	5622699 A	22-04-1997 18-06-1998	
			AU	6374098 A 693723 B	02-07-1998	
			. AU	6973996 A	01-04-1997	
			CA	2204535 A	20-03-1997	
			DE	773441 T	04-03-1999	
			EP	0773441 A	14-05-1997	
•			ĒΡ	0876611 A	11-11-1998	
			JP	10502674 T	10-03-1998	
WO 9726918	Α	31-07-1997	AU	709238 B	26-08-1999	
MO 3120310	^	31 07 1337	AU	1453097 A	20-08-1997	
			EP	0876160 A	11-11-1998	
			NZ	326436 A	29-03-1999	
WO 9810795	Α	19-03-1998	AU	4412297 A	02-04-1998	
MO 3010/33	^	1, 03 1,10	EP	0927045 A	07-07-1999	

# This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

# **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS

IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

FADED TEXT OR DRAWING

BLURRED OR ILLEGIBLE TEXT OR DRAWING

SKEWED/SLANTED IMAGES

COLOR OR BLACK AND WHITE PHOTOGRAPHS

GRAY SCALE DOCUMENTS

LINES OR MARKS ON ORIGINAL DOCUMENT

REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.